MedPage Today  Mar 13  Comment 
(MedPage Today) -- But no new evidence for use in primary prevention of CVD
MedPage Today  Feb 15  Comment 
(MedPage Today) -- Early, elevated diastolic blood pressure predicted mid-life heart disease in whites
MedPage Today  Feb 15  Comment 
(MedPage Today) -- 2015 saw levels once projected for 2030, report says
MedPage Today  Feb 1  Comment 
(MedPage Today) -- Vaping shows physiological effects similar to smoking, not attributable to nicotine
MedPage Today  Jan 14  Comment 
(MedPage Today) -- This week's topics include alcohol abuse and CVD, gun violence in adolescents, social networks and gun violence, and weekend warriors.
MedPage Today  Jan 12  Comment 
(MedPage Today) -- Study is first to suggest mechanism driving the link
GenEng News  Jan 6  Comment 
Novartis is making a $100 million, $61.3 per share equity investment in Ionis Pharmaceuticals and will pay Ionis and the latter’s Akcea Therapeutics subsidiary $75 million upfront as part of a worldwide option and collaboration agreement to...
MedPage Today  Oct 11  Comment 
(MedPage Today) -- Also, difficulties assessing and treating pain
MedPage Today  Sep 29  Comment 
(MedPage Today) -- CT scans identify extra-bad fat accumulations


Covance is an international scientific services company and is known as a Contract Research Organization (CRO). The company is contracted by pharmaceutical, biotechnology, agricultural and medical device companies to perform needed services involving drug and chemical development.

Covance is the second largest CRO in the world in terms of revenue, earning $1.36 billion in nine months of 2008 ending September 30, 2008.[1] In 2007 total revenue was $1.6 billion and in 2006 the company obtained 10% of the total global CRO revenue with revenue of $1.5 billion.[2] Yearly total revenue for the company has increased between 2005 and 2007 by 23.4% due to increases in demand, capacity expansion, acquisitions and selling of one of its businesses.[3] Revenue for Covance is driven primarily by the demand for outsourcing of research and development by pharmaceutical and biotechnology companies., Covance has also increased operating and net income margins between 2003 and 2007 by 16.2% and 29% respectively.[4]

Amidst high development costs, companies are increasingly turning to CROs to help move through the drug development and heavily regulated process to bring products to market quicker and and at a lower cost.[5][6] To take advantage of this trend Covance acquired three companies from 2005 to 2007 totaling $81.9 million and has increased its revenue from international deals by 10% over the past year to $85 million.

Company Overview

Covance provides drug development solutions from preclinical (before human testing) through commercialization for six main areas: biotechnology, pharmaceuticals, food and drug supplements, general research and vaccine testing.

Its services are divided into Early Development and Late Stage Development segments and include: research products, antibody products and services, nonclincal development services, risk assessment services, clinical pharmacology services, central laboratory services, cardiac safety services, clinical development and commercialization services.

Business and Financial Metrics

Operating and Net Income Margins [7]
2003 2004 2005 2006 2007
Operating Margin 12.4% 13.8% 14.7% 14.4% 14.8%
Net Income Margin 8.1% 9.6% 10.0% 10.8% 11.4%

Covance reported $1.36 billion in total revenue in the first three quarters of 2008.[1] The company's revenue increased by 15.4% in 2007 (12.8% when excluding foreign currency fluctuations) to $1.6 billion. This increase was partially due to currency movements, but were primarily determined by a 20% increase in the company's early development segment to $778 million (in revenue) and a 6.3% increase in its late-stage development segment to $769 million (in revenue).[8] Strong growth in the company's clinical development services outweighed decreases in its central laboratory, cardiac safety and commercialization services.[9] Covance also realized gains of $0.4 million due to a minority equity position (approximately 20%) in Bio-Imaging technologies and $2 million due to a minority position (approximately 47%) in Noveprim Limited in 2007.[10] As of Dec. 31, 2007 Covance had no debt and $319 million in cash and cash equivalents. Its operating margin has increased 16.2% over the past five years to 14.8% and its net income margin has increased by 29% over the same period to 11.4%.[4] In February 2007 Covance's Board of Directors authorized a 3 million share buyback plan and at the end of 2007 2.3 million remained for purchase under the plan.[11]

Error creating thumbnail
Net Revenue by Location-2007[12]

Net revenue increased 12.3% in 2006 to $1.34 billion. Revenue changes were partially determined by acquisitions, but were primarily due to growth in its early development and late-stage development segments. Growth in the early development segment was fueled by strong performance in its global toxicology, chemistry and clinical pharmacology services, resulting in a 12.6% increase in net revenue. Strong performance in the company's central laboratory services resulted in a net revenue increase in its late-stage development segment of 12.2%.[13]

Net revenues increased 16.9% in 2005 to $1.19 billion. Net revenue growth was supported by strong performance across service offerings in both segments, resulting in a 17.5% growth in the company's early development segment and a 16.4% net revenue increase in its late-stage development segment.[14]

Acquisitions and Divestitures

In November of 2007 Covance sold its Electrocardiogram (ECG) business ("Cardiac Safety Services"), which was part of its Late Stage Development segment to eResearch Technology Inc. The company received an initial payment of $35.2 million and entered into a ten year agreement under which Covance will continue to offer the cardiac safety services. The deal also stated that Covance will be eligible to receive up to an additional $14 million relating to transferred backlog and future contracts.[15]

To strengthen its Early Development segment, Covance acquired the clinical pharmacology sites of GFI Clinical Services in 2005 for $6.2 million and the clinical pharmacology sites of Radiant Research Inc. in 2006 for $66.6 million. Also, in 2006 the company acquired Signet Laboratories Inc. for $9.1 million.[16]

Business Segments

Error creating thumbnail
Percent of Revenue from Early Stage and Late-Stage Development Segments[8]

Early Development Services (47.7% of FY 2007 Revenue, 60.5% of FY 2007 Operating Income)[8]

Covance's early development services mainly support pre-human testing of animals and in vitro (non-animal models) experiments to develop drug and chemical profiles that if required, will then move into clinical trials. These services generated $778 million in revenue in 2007 and comprise six areas: toxicology, pharmaceutical and nutritional chemistry, bioanalytical, clinical pharmacology and research products.[8] Laboratories exist in Indiana, Wisconsin, Virginia, Germany, Singapore, and the United Kingdom.[17] These services range from testing the effects of compounds on immune systems to the development of research products to aid scientists in compound testing.[17] Early development services utilize StudyTracker, an internet-based program that allows customers of toxicology, bioanalytical, metabolism and reproductive and developmental toxicology services to review study data and schedules on a near real-time basis.[17]

Late Stage Development Services (47.1% of FY 2007 Revenue, 39.5% of FY 2007 Operating Income)[8]

Covance’s late-stage drug development services support human testing of compounds (clinical trials) and commercialization of approved drugs. These services generated $769 million in revenue in 2007 and include central laboratory, clinical development, trial support, and commercialization services.[8] These services range from the initial setup of clinical trials to the (domestic and international) marketing of products. The company has experience conducting clinical trials in North America, Europe, Latin America and the Asia Pacific.[18]

Other Reconciling Items (5.2% of FY 2007 Revenue)[8]

Revenues from other reconciling items are associated with reimbursable out-of-pocket expenses. It also includes depreciation and amortization on corporate fixed assets, as well as corporate expenses such as marketing and communications. These items generated $85.1 million in revenue in 2007.[8]

Gee whiz, and I thouhgt this would be hard to find out.

Articles like these put the conesumr in the driver seat-very important.

Market Share

In 2006 the total market for CRO services was estimated to be $15 billion. Of this Covance had a share of 10%, which equated to $1.5 billion.[2]

Error creating thumbnail
Market Share of $15 Billion Total CRO Market-2006[2]

Back in school, I'm doing so much laerning.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki